Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. Show more
Location: 890 Winter Street, Waltham, MA, 02451, United States | Website: https://upstreambio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
617.6M
52 Wk Range
$5.14 - $29.46
Previous Close
$11.84
Open
$11.68
Volume
164,986
Day Range
$11.45 - $11.85
Enterprise Value
161M
Cash
431.4M
Avg Qtr Burn
-20.69M
Insider Ownership
14.84%
Institutional Own.
89.41%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Verekitug Details Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 Data readout | |
Verekitug Details Severe asthma | Phase 2 Data readout | |
Verekitug Details Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Phase 2 Data readout |